Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.38 USD

74.38
785,910

+0.60 (0.81%)

Updated Aug 19, 2024 11:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead

by Zacks Equity Research

Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.

Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer

by Zacks Equity Research

Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.

Bristol-Myers to Sell French Consumer Health Unit for $1.6B

by Zacks Equity Research

Bristol-Myers (BMY) receives a $1.6 billion offer for its French consumer health unit from Japanese company, Taisho.

    Gilead Partners with Scholar Rock for Fibrotic Disease Drugs

    by Zacks Equity Research

    Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.

      Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint

      by Zacks Equity Research

      Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.

      Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod

      by Zacks Equity Research

      Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.

      Evofem Shares Up as Birth Control Gel Succeeds in Phase III

      by Zacks Equity Research

      Evofem (EVFM) stock surges on positive results from a late-stage study on experimental birth control vaginal gel.

      Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer

      by Zacks Equity Research

      Puma Biotech (PBYI) reports positive top-line data from the phase III NALA study, conducted on its breast cancer drug Nerlynx in third-line setting.

      Gilead Sciences (GILD) Stock Moves -0.69%: What You Should Know

      by Zacks Equity Research

      Gilead Sciences (GILD) closed the most recent trading day at $65.12, moving -0.69% from the previous trading session.

      Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus

      by Zacks Equity Research

      Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.

      AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals

      by Zacks Equity Research

      AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.

      Kinjel Shah headshot

      5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

      by Kinjel Shah

      There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.

      The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis

      Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals

      by Zacks Equity Research

      Bausch (BHC) bids to acquire certain assets of Synergy Pharma for $200 million.

      Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

      by Zacks Equity Research

      A low key week for the biotech sector with focus on regular pipeline updates.

      The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

      Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO

      by Zacks Equity Research

      Gilead Sciences (GILD) names Roche's Daniel O'Day as the company's new Chairman and CEO.

      Ekta Bagri headshot

      4 Biotech Stocks Investors Can Add to Their Portfolio in 2019

      by Ekta Bagri

      Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.

      Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

      by Zacks Equity Research

      Gilead Sciences (GILD) closed at $67.49 in the latest trading session, marking a -0.97% move from the prior day.

      Roche's Tecentriq Gets FDA Approval for First-Line NSCLC

      by Zacks Equity Research

      Roche's (RHHBY) Tecentriq in combination with Avastin obtains FDA nod for the initial treatment of NSCLC.

      Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis

      by Zacks Equity Research

      Biogen (BIIB) obtains a license to develop and commercialize BIIB067 from Ionis Pharmaceuticals. The candidate is being developed for treatment of ALS with SOD1 mutations.

      Gilead's (GILD) Harvoni and Descovy Get Approval in China

      by Zacks Equity Research

      Gilead's (GILD) HCV drug Harvoni and HIV cocktail therapy Descovy get approval in China.

      Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China

      by Zacks Equity Research

      This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector.

      Amgen's BiTE Immunotherapies Show Promise in Early Studies

      by Zacks Equity Research

      Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA

      Gilead (GILD) Announces Data on CAR T Therapy Candidate

      by Zacks Equity Research

      Gilead (GILD) announces data on chimeric antigen receptor T (CAR T) cell therapy candidate at the ASH for the treatment of patients with relapsed or refractory acute lymphoblastic leukemia.